Recent Advances in Multiple Myeloma: Applying Real-World Evidence to Clinical Practice - Episode 11

The GMMG HD7 Trial of Isa-VRd vs VRd in Transplant-Eligible NDMM


An expert reviews data from the ongoing GMMG HD7 (German) trial investigating isatuximab in combination with bortezomib, lenalidomide and dexamethasone (Isa-VRd) versus VRd in the treatment of transplant-eligible newly diagnosed multiple myeloma.